GSK Fined $54M Over UK 'Pay-For-Delay' Deals

Law360, New York (February 12, 2016, 11:03 AM EST) -- United Kingdom antitrust regulators on Friday announced a £37.6 million ($54.3 million) fine against GlaxoSmithKline PLC after concluding that the drugmaker orchestrated improper “pay-for-delay” deals to postpone generic versions of blockbuster antidepressant Seroxat.

The Competition and Markets Authority levied the penalty in connection with deals worth £50 million that GSK struck from 2001 to 2004 to protect sales of Seroxat, or paroxetine, which is sold in the United States as Paxil.

According to the authority, the deals included cash and "the effective transfer from GSK of...
To view the full article, register now.